The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Related articles:
Related suggestion:
Exhibition Featuring Paintings by Children of Xinjiang Held in BeijingReport: Nearly 60 Percent of Women in Flexible Employment Have Stable Average Monthly EarningsChina Post Issues Commemorative Stamp to Mark 10th Anniversary of BRITravel prices for May Day holiday surge70th Anniversary of Founding of Gannan Tibetan Autonomous Prefecture Celebrated in GansuApps simplify expense steps for foreign usersExperts Restore Terracotta Warriors in Xi'anAsian Games Torch Relay Highlights History, Vitality of JiaxingChina's EightAuthorities Plan Major HPV Vaccine Drive
3.0201s , 6496.625 kb
Copyright © 2024 Powered by It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start? ,International Index news portal